We are actively working to establish additional syngeneic and humanized ovarian cancer models with better representation of the genetic landscape of OCs to further determine whether oncogenic alterations, such as TP53 mutation, influence the METTL5/ATF4/Ferroptosis axis in tumor immune evasion. This evidence concerns the gene ATF4 and ovarian carcinoma.